Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.
Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.
Health insurance companies probably finding some obscure study to deny claims for Paxlovid. Or just follow UHC claim practices. Deny all claims initially. Slow roll it.
Patient either gives up or pays out of pocket.
I’m guessing they’ll claim it lacks sufficient evidence for it’s efficacy and call it experimental.